- Strong Generic Oral Contraceptive Sales
- Strong Alliance and Development Revenue
- PLIVA Integration Remains on Track
- Company Reiterates Calendar 2007 Adjusted EPS Guidance of $3.00 - $3.30
WOODCLIFF LAKE, N.J., Aug. 8 /PRNewswire-FirstCall/ -- Barr
Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $45.3
million, or $0.41 per share, for the quarter ended June 30, 2007, compared
to net earnings of $82.3 million, or $0.76 per share, for the same period
last year. Revenues for the current quarter totaled $637 million, compared
to $352 million for the same period last year. Adjusted earnings per share
were $0.84 for the second quarter of 2007, compared to adjusted earnings
per share of $0.93 in the prior year period. A reconciliation of GAAP-based
earnings per share to adjusted earnings per share is presented in the table
at the end of this press release.
For the six months ended June 30, 2007, net earnings were $56.9
million, or $0.52 per share, compared to $158.4 million, or $1.46 per
share, in the prior year period. Revenues for the first six months of 2007
totaled $1.2 billion, compared to $679 million for the same period last
year. Adjusted earnings per share were $1.62 for the six months ended June
30, 2007, compared to adjusted earnings per share of $1.77 in the prior
year period.
"Our strong results for the quarter reflect sound contributions from
both our generic and brand segments," said Bruce L. Downey, Barr's Chairman
and Chief Executive Officer. "In addition to strong generic oral
contraceptive sales, we also experienced strong performance in the U.S.
proprietary business from our Plan B(R) emergency contraceptive and
ParaGard(R) IUD product. Royalties related to our Allegra(R) agreement with
Teva boosted alliance and development revenue for the quarter as well. When
we look across the global business, the integration of PLIVA continues to
progress well, we continued to invest in our future through $65 million in
product development expenditures during the second quarter, and we
initiated our direct-to-consumer marketing campaign for the SEASONIQUE(R)
extended-cycle oral contraceptive at the beginning of the third quarter.
Overall, we are very pleased with the performance of the business during
the first half of 2007."
Revenues
Generic Product Sales
Sales of the Company's generic products increased to $487 million for
the second quarter of 2007, compared to $222 million in the prior year
period. For the first six months of 2007, generic product sales increased
to $961 million, compared to $423 million for the prior year period. A
discussion of the Company's generic product sales for the second quarter of
2007 compared to the prior year period is presented below.
U.S. Generic Sales
Sales of U.S. generic products totaled $296 million for the second quarter
of 2007, compared to $222 million in the prior year period. The increase
in sales is primarily related to the inclusion of sales from PLIVA's U.S.
product line. These products are now being sold under the Barr label. The
increase also reflects strong sales of Fentanyl Citrate, a generic version
of ACTIQ(R) that we launched in late September 2006, and higher generic
oral contraceptive sales.
Sales of generic oral contraceptives, the Company's largest single
category of generic products, were $116 million for the second quarter of
2007, compared to $107 million in the prior year period. This growth is
primarily related to sales of Balziva(TM) and Jolessa(TM), which the
Company launched in October 2006 and September 2006, respectively, as well
as to increased sales of Kariva(R).
Europe and Rest of the World ("ROW") Generic Sales
Sales of generic products in Europe and the ROW through our PLIVA
subsidiary were $191 million in the second quarter of 2007. Revenues were
primarily driven by sales of PLIVA products in the key markets of Germany,
Croatia, Poland and Russia. Prior to the Company's acquisition of PLIVA in
October 2006, Barr did not have any product sales in Europe or the ROW.
Proprietary Product Sales
The Company's proprietary product sales were $102 million for the
second quarter of 2007, compared to $97 million in the prior year period.
For the first six months of 2007, proprietary product sales were $191
million, the same as in the prior year period. For the second quarter, the
$5 million increase in proprietary sales was primarily attributable to
higher sales of Plan B(R) Over-the-Counter/Rx and Adderall(R) IR, both of
which were launched in the quarter ended December 31, 2006, and sales of
SEASONIQUE(R) which was launched in August 2006. These increases more than
offset lower sales of our SEASONALE(R) extended-cycle oral contraceptive,
which faced generic competition in September 2006 following the expiration
of three years of market exclusivity.
Alliance and Development Revenue
During the second quarter of 2007, the Company reported alliance and
development revenue of $36 million, compared to $32 million in the prior
year period. For the first six months of 2007, alliance and development
revenue was $62 million, down from $65 million in the prior year period.
The increase for the quarter ended June 30, 2007 reflects reimbursement
under the Shire agreement that was entered into in August 2006 and higher
reimbursement from the Adenovirus agreement with the U.S. Department of
Defense.
Other Revenue
Other revenue primarily includes revenue from non-core operations
acquired in connection with the PLIVA acquisition, including the
diagnostic, disinfectants, dialysis and infusions business. Other revenue
totaled $12 million for the second quarter of 2007 and $22 million for the
first six months of 2007.
Margins
Generic: Margins in the generic segment for the second quarter of 2007
and the first six months of 2007 were 48% and 46%, respectively, down from
65% and 65%, respectively, in the prior year periods. Generic margins for
the quarter ended June 30, 2007 were negatively impacted by amortization
costs arising from the PLIVA acquisition.
Proprietary: Margins in the proprietary segment for the second quarter
of 2007 and the first six months of 2007 were 79% and 73%, respectively, up
from 69% and 70%, respectively, in the prior year periods. Proprietary
margins for the quarter ended June 30, 2007 increased primarily due to the
launch of SEASONIQUE and a stronger mix of higher margin product sales.
Update on R&D Activities
Research and development investment totaled $65 million for the second
quarter of 2007, compared to $36 million in the prior year period. R&D for
the first six months of 2007 totaled $127 million, compared to $74 million
for the prior year period. The significant increases reflect greater
investment in generic and bio-generic development activities, both in the
U.S. and Europe, as well as in proprietary development activities in the
United States.
Generic Products
At June 30, 2007, the Company had approximately 60 Abbreviated New Drug
Applications, including tentatively approved applications, pending at the
U.S. Food and Drug Administration (FDA) targeting branded pharmaceutical
products with an estimated $30 billion in sales. The Company also had
approximately 230 product registrations, representing 78 molecules, pending
with regulatory bodies in Europe and in the ROW.
During the second quarter of 2007, the Company received seven generic
product approvals in the U.S. from the FDA, including tentative approvals,
and 25 approvals, representing 23 molecules, from regulatory bodies in
Europe and in the ROW.
Proprietary Products
The Company currently has an extensive proprietary clinical development
program that includes six products in Phase III studies and several New
Drug Applications pending at the FDA. During the quarter, the Company
received two FDA approvals related to its ENJUVIA(TM) (synthetic conjugated
estrogens, B) product.
Selling, General and Administrative
The Company's SG&A expenses totaled $189 million during the second
quarter of 2007, compared to $104 million in the prior year period. SG&A
for the first six months of 2007 totaled $370 million, compared to $182
million for the prior year period. The substantial increase in SG&A for the
quarter and six months ended June 30, 2007 is primarily attributable to the
addition of PLIVA's sales and marketing activities, including, but not
limited to, the costs associated with approximately 1,400 sales
representatives that PLIVA utilizes to promote branded generic products to
physicians and pharmacists in many countries, and other general and
administrative expenses associated with our worldwide operations.
Interest Expense/Income and Other Income
During the second quarter of 2007, the Company recorded $42 million of
interest expense, almost all of which is related to interest on the $2.6
billion of debt incurred in connection with the PLIVA acquisition and a
one- time bank fee associated with a bridge loan related to the
acquisition. The Company recorded $0.3 million of interest expense in the
prior year period.
During the second quarter of 2007, interest income increased by $2
million over the prior year period. This increase was primarily related to
higher available balances invested during the second quarter of 2007 as
compared to the prior year period, in addition to rising interest rates.
Other income in the second quarter of 2007 totaled $3.7 million and
included a gain of $3.5 million relating to the unwinding of a treasury
lock on a ten-year U.S. Treasury security that was used to hedge forecast
interest payments.
Stock-Based Compensation
During the second quarter of 2007, the Company recorded stock-based
compensation expenses of $8.1 million, or $0.05 per share. For the first
six months of 2007, the Company recorded stock-based compensation expenses
of $15.4 million, or $0.10 per share. The impact for the quarter and the
six months ended June 30, 2007 is allocated to cost of sales, SG&A and R&D,
and is reflected in the accompanying selected adjusted financial data
chart.
Tax Rate
The Company's tax rate for second quarter of 2007 was 35.5%, compared
to 34.6% for the prior year period. For the first six months of 2007, the
tax rate was 37.1%, compared to 34.9% for the prior year period. The
increase in the reported effective tax rate is primarily due to the impact
of purchase accounting adjustments related to the PLIVA acquisition, losses
incurred in certain legal entities without a tax benefit and additional
U.S. taxes related to the PLIVA acquisition. The increase was somewhat
offset by benefits realized related to the enactment of the research and
development incentive in Croatia, retroactive to the beginning of the tax
year, as well as the release of certain FIN 48 tax liabilities related to
audit settlements in various tax jurisdictions.
Balance Sheet
The Company's cash, cash equivalents and marketable securities totaled
approximately $767.5 million and its debt totaled $2.5 billion at June 30,
2007.
EBITDA
Earnings before interest, taxes, depreciation and amortization,
including amortization of inventory step-up charges (EBITDA), for the
second quarter of 2007 totaled $175 million, compared to $130 million in
the prior year period. For the first six months of 2007, EBITDA totaled
$331 million, compared to $269 million for the prior year period. Please
see the reconciliation table at the end of this press release for the
calculation of EBITDA.
2007 Financial Outlook
The Company is reiterating that it expects adjusted earnings per fully
diluted share for the year ending December 31, 2007 to be in the range of
approximately $3.00 - $3.30. The adjustments are discussed in the paragraph
immediately below. The Company expects total revenues for 2007 to be in the
range of $2.4 - $2.5 billion, including total product sales in the range of
$2.3 - $2.4 billion. On the expense side, the Company now expects slightly
higher R&D investment of approximately $250 - $255 million, and continues
to expect SG&A expenses to be approximately $740 - $760 million.
The Company's adjusted guidance for 2007 excludes amortization costs
associated with acquired products, charges related to the step-up of
inventory acquired from PLIVA, contributions from operations that the
Company anticipates divesting during 2007, incremental depreciation related
to the step-up of PLIVA's assets, the tax impact related to PLIVA's U.S.
net operating losses and stock-based compensation costs. The Company's
adjusted guidance for 2007 also excludes the impact of potential patent
challenge outcomes, other business development activities, and potential
refinancing activities that may be completed by December 31, 2007.
Conference Call/Webcast
The Company will host a Conference Call at 8:30 AM Eastern time on
Wednesday, August 8th to discuss earnings results for the quarter and six-
month period ended June 30, 2007. The number to call from within the United
States is: (800) 230-1059 and (612) 234-9960 Internationally. A replay of
the conference call will be available from 12 Noon Eastern time on August
8th through 11:59 PM Eastern time August 22nd, and can be accessed by
dialing (800) 475-6701 in the United States or (320) 365-3844
Internationally and using the access code 879946.
The conference call will also be webcast live on the Internet.
Investors and other interested parties may access the live webcast through
the Investors section, under Calendar of Events, on Barr's website at
http://www.barrlabs.com. Log on at least 15 minutes before the call begins to
register and download or install any necessary audio software.
About Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company
that operates in more than 30 countries worldwide and is engaged in the
development, manufacture and marketing of generic and proprietary
pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.
A holding company, Barr operates through its principal subsidiaries Barr
Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. The Barr
group of companies markets more than 115 generic and 25 proprietary
products in the U.S. and more than 1,200 products globally outside of the
U.S.
Forward-Looking Statements
Except for the historical information contained herein, the statements
made in this press release constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements can be
identified by their use of words such as "expects," "plans," "projects,"
"will," "may," "anticipates," "believes," "should," "intends," "estimates"
and other words of similar meaning. Because such statements inherently
involve risks and uncertainties that cannot be predicted or quantified,
actual results may differ materially from those expressed or implied by
such forward-looking statements depending upon a number of factors
affecting the Company's business. These factors include, among others: the
difficulty in predicting the timing and outcome of legal proceedings,
including patent-related matters such as patent challenge settlements and
patent infringement cases; the outcome of litigation arising from
challenging the validity or non- infringement of patents covering our
products; the difficulty of predicting the timing of FDA approvals; court
and FDA decisions on exclusivity periods; the ability of competitors to
extend exclusivity periods for their products; our ability to complete
product development activities in the timeframes and for the costs we
expect; market and customer acceptance and demand for our pharmaceutical
products; our dependence on revenues from significant customers;
reimbursement policies of third party payors; our dependence on revenues
from significant products; the use of estimates in the preparation of our
financial statements; the impact of competitive products and pricing on
products, including the launch of authorized generics; the ability to
launch new products in the timeframes we expect; the availability of raw
materials; the availability of any product we purchase and sell as a
distributor; the regulatory environment in the markets where we operate;
our exposure to product liability and other lawsuits and contingencies; the
increasing cost of insurance and the availability of product liability
insurance coverage; our timely and successful completion of strategic
initiatives, including integrating companies (such as PLIVA d.d.) and
products we acquire and implementing our new SAP enterprise resource
planning system; fluctuations in operating results, including the effects
on such results from spending for research and development, sales and
marketing activities and patent challenge activities; the inherent
uncertainty associated with financial projections; our expansion into
international markets through our PLIVA acquisition, and the resulting
currency, governmental, regulatory and other risks involved with
international operations; our ability to service our significantly
increased debt obligations as a result of the PLIVA acquisition; changes in
generally accepted accounting principles; and other risks detailed in our
SEC filings, including in our Transition Report on Form 10-K/T for the six
months ended December 31, 2006.
The forward-looking statements contained in this press release speak
only as of the date the statement was made. The Company undertakes no
obligation (nor does it intend) to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except to the extent required under applicable law.
Barr Pharmaceuticals, Inc. Selected Financial Data
(in thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
(unaudited) (unaudited) (unaudited) (unaudited)
Revenues:
Product sales $588,901 $319,619 $1,152,719 $613,140
Alliance and development
revenue 36,423 32,049 61,544 65,369
Other revenue 11,626 - 22,065 -
Total revenues 636,950 351,668 1,236,328 678,509
Costs and expenses:
Cost of sales 277,613 107,328 580,148 205,835
Selling, general and
administrative 189,364 104,303 370,229 182,460
Research and development 65,413 36,447 126,637 74,152
Write-off of acquired
IPR&D 2,809 - 4,358 -
Earnings from operations 101,751 103,590 154,956 216,062
Interest income 8,133 5,734 18,755 9,947
Interest expense 41,798 289 83,567 456
Other income (expense) 3,730 16,690 4,826 17,761
Earnings before income taxes
and minority interest 71,816 125,725 94,970 243,314
Income tax expense 25,520 43,471 35,245 84,964
Minority interest (376) - (1,911) -
Net earnings from continuing
operations 45,920 82,254 57,814 158,350
Loss from discontinued
operations, net of taxes (575) - (897) -
Net earnings $45,345 $82,254 $56,917 $158,350
Earnings per common share -
diluted:
Earnings per common share -
continuing operations $0.42 $0.76 $0.53 $1.46
Loss per common share -
discontinued operations (0.01) - (0.01) -
Net earnings per common share -
diluted $0.41 $0.76 $0.52 $1.46
Weighted average shares -
diluted 108,191 108,084 108,124 108,399
Stock-based compensation
expense:
Cost of sales $2,319 $1,745 $4,512 $3,757
Selling, general and
administrative 4,409 3,230 8,223 6,728
Research and development 1,405 1,290 2,697 2,713
Total stock-based compensation
expense $8,133 $6,265 $15,432 $13,198
As of As of
Select Balance Sheet Data 6/30/07 12/31/06
Cash & cash equivalents $203,956 $231,975
Marketable securities -
Current and long-term 563,565 682,692
Accounts receivable, net 477,080 515,303
Other receivables 68,099 76,491
Inventories, net 457,776 429,592
Accounts payable & accrued
liabilities 380,504 425,443
Working capital 879,339 876,106
Total assets 4,808,752 4,961,862
Total debt 2,458,612 2,677,669
Shareholders' equity 1,604,336 1,465,228
Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA
To supplement its consolidated financial statements presented in
accordance with accounting principles generally accepted in the United
States of America ("GAAP"), the Company is providing the supplemental
financial information contained below to reflect (1) the adjusted earnings
per share effect of certain unusual or infrequent charges or benefits that
were taken or received in the three and six months ended June 30, 2007, and
(2) the calculation of EBITDA for each period presented.
Adjusted earnings per share and EBITDA are non-GAAP financial measures.
The Company is providing this information, however, because it believes
that such information is useful to both management and investors in that it
facilitates analysis by both management and investors in evaluating the
Company's performance and trends. The presentation of this additional
information is not meant to be considered in isolation of, or as a
substitute for, results prepared in accordance with GAAP.
Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data
(in thousands, except per share amounts)
Three Months Ended June 30, 2007
Adjusted
GAAP Adjustments Earnings
Revenues:
Product sales $588,901 - $588,901
Alliance and development revenue 36,423 - 36,423
Other revenue 11,626 - 11,626
Total revenues 636,950 - 636,950
Costs and expenses:
Cost of sales 277,613 (47,440) (b)(c)(d) 230,173
Selling, general and
administrative 189,364 (6,553) (b)(c)(d)(f) 182,811
Research and development 65,413 (1,552) (b)(c)(d) 63,861
Write-off of acquired IPR&D 2,809 (2,809) (e) -
Earnings from operations 101,751 58,354 160,105
Interest income 8,133 - 8,133
Interest expense 41,798 - 41,798
Other income, net 3,730 - 3,730
Earnings before income taxes and
minority interest 71,816 58,354 741 130,911
Income tax expense 25,520 13,520 (j) 39,040
Minority interest 376 142 14 532
Net earnings from continuing
operations 45,920 44,692 727 (a) 91,339
Loss from discontinued
operations, net of taxes (575) 575 (k) -
Net earnings $45,345 $45,267 $727 $91,339
Basic
Earnings per common share -
continuing operations $0.43 $0.85
Earnings per common share -
discontinued operations $(0.01) $-
Net earnings per common share -
basic $0.42 $0.85
Weighted average shares - basic 106,909 106,909
Diluted
Earnings per common share -
continuing operations $0.42 $0.84
Earnings per common share -
discontinued operations $(0.01) $-
Net earnings per common share -
diluted $0.41 $0.84
Weighted average shares - diluted 108,191 108,191
Three Months Ended June 30, 2006
Adjusted
GAAP Adjustments Earnings
Revenues:
Product sales $319,619 $- $319,619
Alliance and development revenue 32,049 - 32,049
Other revenue - - -
Total revenues 351,668 - 351,668
Costs and expenses:
Cost of sales 107,328 (18,681) (b)(d) 88,647
Selling, general and administrative 104,303 (25,730) (d)(g) 78,573
Research and development 36,447 (1,290) (d) 35,157
Write-off of acquired IPR&D - - -
Earnings from operations 103,590 45,701 149,291
Interest income 5,734 - 5,734
Interest expense 289 - 289
Other income, net 16,690 (17,000) (h)(i) (310)
Earnings before income taxes and
minority interest 125,725 28,701 154,426
Income tax expense 43,471 10,506 (j) 53,977
Minority interest - - -
Net earnings from continuing
operations 82,254 18,195 100,449
Loss from discontinued operations,
net of taxes - - -
Net earnings $82,254 $18,195 $100,449
Basic
Earnings per common share -
continuing operations $0.77 $0.95
Earnings per common share -
discontinued operations $- $-
Net earnings per common share - basic $0.77 $0.95
Weighted average shares - basic 106,185 106,185
Diluted
Earnings per common share -
continuing operations $0.76 $0.93
Earnings per common share -
discontinued operations $- $-
Net earnings per common share -
diluted $0.76 $0.93
Weighted average shares - diluted 108,084 108,084
Summary Of Adjustment Items:
Three Months Ended June 30,
2007 2006
(a) Net loss from operations expected
to be divested, net of minority interest (727) -
These businesses are expected to be divested
by early 2008. The Company believes adjusting
GAAP earnings for these losses will allow
investors to better assess our ongoing
activities.
(b) Amortization and inventory step up adjustments:
Cost of sales -
Inventory step up - PLIVA (448) -
Inventory step up - FEI (8,289)
PLIVA-related product amortization (29,040) -
Barr product amortization (11,114) (8,647)
Subtotal Cost of sales (40,602) (16,936)
PLIVA - Selling, general and administrative (281)
PLIVA - Research and development (18) -
Total (40,901) (16,936)
(c) Incremental PLIVA depreciation
due to purchase accounting write up
of fixed assets:
Cost of sales (4,519) -
Selling, general and administrative (363) -
Research and development (129) -
Total (5,011) -
(d) Stock option expense:
Cost of sales (2,319) (1,745)
Selling, general and administrative (4,409) (3,230)
Research and development (1,405) (1,290)
Total (8,133) (6,265)
(e) Write off of acquired IPR&D
associated with purchase of PLIVA equity
(2,809) -
(f) Litigation reserve (1,500) -
(g) Litigation settlement - Invamed - (22,500)
(h) Unrealized gain on venture fund - 6,700
(i) Foreign currency hedge appreciation - 10,300
(j) Adjustments to tax expense, including:
Tax impact of adjustments (A) -
(I) above. 16,145 10,506
Tax (benefit) from recognition
of acquired NOL (2,625) -
Total 13,520 10,506
(k) In order to provide investors and
management a basis to evaluate the
performance of the ongoing
operations, adjusted earnings
exclude the impact of discontinued
operations
Accounted for as discontinued
operations 575 -
EBITDA Calculation:
Three Months Ended June 30,
2007 2006
Earnings from operations $101,751 $103,590
Depreciation 32,838 9,794
Amortization 40,453 8,647
Inventory step up 448 8,289
EBITDA $175,490 $130,320
Barr Pharmaceuticals, Inc. Selected Adjusted Financial Data
(in thousands, except per share amounts)
Six Months Ended June 30, 2007
Adjusted
GAAP Adjustments Earnings
Revenues:
Product sales $1,152,719 - $1,152,719
Alliance and development
revenue 61,544 - 61,544
Other revenue 22,065 - 22,065
Total revenues 1,236,328 - 1,236,328
Costs and expenses:
Cost of sales 580,148 (126,026) (b)(c)(d) 454,122
Selling, general and
administrative 370,229 (17,660) (c)(d)(f) 352,569
Research and development 126,637 (3,004) (c)(d) 123,633
Write-off of acquired IPR&D 4,358 (4,358) (e) -
Earnings from operations 154,956 151,048 306,004
Interest income 18,755 - 18,755
Interest expense 83,567 - 83,567
Other income, net 4,826 - 4,826
Earnings before income
taxes and minority
interest 94,970 151,048 2,509 248,527
Income tax expense 35,245 36,018 (j) 71,263
Minority interest 1,911 239 61 2,211
Net earnings from
continuing operations 57,814 114,791 2,448 (a) 175,053
Loss from discontinued
operations, net of taxes (897) 897 (h) -
Net earnings $56,917 $115,688 $2,448 $175,053
Basic
Earnings per common share
- continuing operations $0.54 $1.64
Earnings per common share
- discontinued operations $(0.01) $-
Net earnings per common
share - basic $0.53 $1.64
Weighted average shares -
basic 106,909 106,909
Diluted
Earnings per common share
- continuing operations $0.53 $1.62
Earnings per common share
- discontinued operations $(0.01) $-
Net earnings per common
share - diluted $0.52 $1.62
Weighted average shares -
diluted 108,124 108,124
Six Months Ended June 30, 2006
Adjusted
GAAP Adjustments Earnings
Revenues:
Product sales $613,140 $- $613,140
Alliance and development revenue 65,369 - 65,369
Other revenue - - -
Total revenues 678,509 - 678,509
Costs and expenses:
Cost of sales 205,835 (37,352) (b)(d) 168,483
Selling, general and administrative 182,460 (29,228) (d)(g) 153,232
Research and development 74,152 (2,713) (d) 71,439
Write-off of acquired IPR&D - - -
Earnings from operations 216,062 69,293 285,355
Interest income 9,947 - 9,947
Interest expense 456 - 456
Other income, net 17,761 (17,000) (h)(i) 761
Earnings before income taxes and
minority interest 243,314 52,293 295,607
Income tax expense 84,964 19,070 (j) 104,034
Minority interest - - -
Net earnings from continuing
operations 158,350 33,223 191,573
Loss from discontinued operations, net
of taxes - - -
Net earnings $158,350 $33,223 $191,573
Basic
Earnings per common share - continuing
operations $1.49 $1.81
Earnings per common share -
discontinued operations $- $-
Net earnings per common share - basic $1.49 $1.81
Weighted average shares - basic 106,009 106,009
Diluted
Earnings per common share - continuing
operations $1.46 $1.77
Earnings per common share -
discontinued operations $- $-
Net earnings per common share -
diluted $1.46 $1.77
Weighted average shares - diluted 108,399 108,399
Summary Of Adjustment Items:
Six Months Ended June 30,
2007 2006
(a) Net loss from operations
expected to be divested, net of
minority interest (2,448) -
These businesses are expected to be
divested by early 2008. The Company
believes adjusting GAAP earnings for
these losses will allow investors to
better assess our ongoing activities.
(b) Amortization and inventory step
up adjustments:
Cost of Sales -
Inventory step up - PLIVA (32,758) -
Inventory step up - FEI (16,083)
PLIVA-related product
amortization (57,236) -
PLIVA-related intangible asset
amortization -
Barr product amortization (22,813) (17,512)
Subtotal cost of sales (112,807) (33,595)
PLIVA - Selling, general and administrative (708) -
PLIVA - Research and development (40) -
Total (113,555) (33,595)
(c) Incremental PLIVA Depreciation
due to purchase accounting write up
of fixed assets:
Cost of sales (8,707) -
Selling, general and administrative (729) -
Research and development (267) -
Total (9,703) -
(d) Stock option expense:
Cost of sales (4,512) (3,757)
Selling, general and administrative (8,223) (6,728)
Research and development (2,697) (2,713)
Total (15,432) (13,198)
(e) Write off of acquired IPR&D
associated with additional PLIVA
shares:
(4,358) -
(f) Litigation reserve (8,000) -
(g) Litigation settlement - Invamed - (22,500)
(h) Unrealized gain on venture fund - 6,700
(i) Foreign currency hedge appreciation - 10,300
(j) Adjustments to tax expense, including:
Tax impact of adjustments (A) -
(I) above. 41,168 19,070
Tax (benefit) from recognition
of acquired NOL (5,150) -
Total 36,018 19,070
(k) In order to provide investors and
management a basis to evaluate the
performance of the ongoing
operations, adjusted earnings
exclude the impact of discontinued
operations
Accounted for as discontinued operations 897 -
EBITDA Calculation:
Six Months Ended June 30,
2007 2006
Earnings from operations $154,956 $216,062
Depreciation 62,847 18,883
Amortization 80,797 17,512
Inventory step up 32,758 16,083
EBITDA $331,358 $268,540
SOURCE Barr Pharmaceuticals, Inc.
 back to top
Related links:
http://www.barrlabs.com
http://www.prnewswire.com/comp/089750.html /
CONTACT:
Carol A. Cox, +1-201-930-3720,
ccox@barrlabs.com
|
